Cargando…

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions

SIMPLE SUMMARY: Feline mammary neoplasias are highly prevalent in domestic cats and present many similarities to their human counterparts. Since information about benign feline mammary lesions is still scarce and often controversial, studies using a wider panel of oncological biomarkers are necessar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soares, Maria, Correia, Assunção N., Batista, Mariana R., Correia, Jorge, Ferreira, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264830/ https://www.ncbi.nlm.nih.gov/pubmed/35804497 http://dx.doi.org/10.3390/ani12131599

Ejemplares similares

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

An immunohistochemical study on the expression of sex steroid receptors, Ki-67 and cytokeratins 7 and 20 in feline endometrial adenocarcinomas
por: Saraiva, Ana Laura, et al.
Publicado: (2015)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression
por: Mukhopadhyay, Madhumita, et al.
Publicado: (2017)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity
por: Hamed, Mahmood A., et al.
Publicado: (2017)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
por: Joensuu, Kristiina, et al.
Publicado: (2013)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
por: Subik, Kristina, et al.
Publicado: (2010)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
por: Tyuryumina, Ella Ya., et al.
Publicado: (2020)

Breast Carcinoma – A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters
por: K, Sajitha, et al.
Publicado: (2022)

Intra-tumoral distribution of Ki-67 and Cyclin D1 in ER+ mammary carcinoma: quantitative evaluation
por: Latifa, Mohammedi, et al.
Publicado: (2021)

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
por: Sinn, Hans-Peter, et al.
Publicado: (2017)

Cytokeratin 17 and Ki-67: Immunohistochemical markers for the differential diagnosis of keratoacanthoma and squamous cell carcinoma
por: Leblebici, Cem, et al.
Publicado: (2017)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Evaluation of Ki-67 expression in feline non-ocular melanocytic tumours
por: Sabattini, Silvia, et al.
Publicado: (2018)

Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study
por: Afkari, Hanif, et al.
Publicado: (2021)

Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers
por: Adisa, James Olayiwola, et al.
Publicado: (2015)

Gene expression association study in feline mammary carcinomas
por: Ferreira, Daniela, et al.
Publicado: (2019)

Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes
por: Marques, Cláudia S., et al.
Publicado: (2017)

Apoptosis and Ki-67 as predictive factors for response to radiation therapy in feline nasal lymphomas
por: FU, Dah-Renn, et al.
Publicado: (2016)

A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
por: Hadad, Sirwan M., et al.
Publicado: (2016)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
por: Gameiro, Andreia, et al.
Publicado: (2021)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
por: Tuominen, Vilppu J, et al.
Publicado: (2010)

Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study
por: Shokouh, Taghipour Zahir, et al.
Publicado: (2015)

Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases
por: Peng, Li, et al.
Publicado: (2021)

Prognostic significance of Ki67 in Chinese women diagnosed with ER(+)/HER2(−) breast cancers by the 2015 St. Gallen consensus classification
por: Hu, Yue, et al.
Publicado: (2017)

Protein co-expression networks identified from HOT lesions of ER+HER2–Ki-67high luminal breast carcinomas
por: Yamada, Kimito, et al.
Publicado: (2021)

Immunohistochemistry of mammary Paget’s disease: Cytokeratin 7, GATA3, and HER2 are sensitive markers
por: Arain, Shoukat A., et al.
Publicado: (2020)

External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China
por: Pu, Tianjie, et al.
Publicado: (2019)

ER and PR signaling nodes during mammary gland development
por: Tanos, Tamara, et al.
Publicado: (2012)

Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women
por: Singhai, Rajeev, et al.
Publicado: (2011)

Invasive Colloid Carcinoma and the role of Ki-67 and HER2 – Two case reports
por: Patel, Sarvanand, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mvid8khpa7mfh3g67dibpnqiks